And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to catch up on our reading, promenade with the official mascot and watch some footie on the telly. And what about you? This may be a good opportunity to catch up on chores or reach out to someone feeling isolated. Or you may want to place your bets on the fate of a certain someone in D.C. Well, whatever you do, have a grand time. But be safe. Enjoy — and wear a mask. …

The Covid-19 vaccine developed by Pfizer (PFE) and BioNTech (BNTX) appeared to work against a key mutation in highly transmissible new variants of the coronavirus discovered in the U.K. and South Africa, STAT notes. The result is evidence existing vaccines will be able to withstand some mutations without losing efficacy. But experts noted this vaccine and others will still need to be tested against other mutations of concern, and the new study only looked at one key mutation contained in the variants, not the full variants.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]